X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PANACEA BIOTECH ALEMBIC PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 18.0 -6.9 - View Chart
P/BV x 4.6 2.2 205.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
PANACEA BIOTECH
Mar-14
ALEMBIC PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs645149 433.8%   
Low Rs47082 570.8%   
Sales per share (Unadj.) Rs166.184.1 197.4%  
Earnings per share (Unadj.) Rs21.9-18.3 -119.6%  
Cash flow per share (Unadj.) Rs27.5-6.7 -410.4%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs117.883.7 140.7%  
Shares outstanding (eoy) m188.5261.25 307.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 244.5%   
Avg P/E ratio x25.5-6.3 -403.5%  
P/CF ratio (eoy) x20.3-17.2 -117.6%  
Price / Book Value ratio x4.71.4 343.1%  
Dividend payout %18.30-   
Avg Mkt Cap Rs m105,0907,074 1,485.5%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m6,2281,449 429.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m31,3085,154 607.5%  
Other income Rs m70100 70.4%   
Total revenues Rs m31,3785,254 597.3%   
Gross profit Rs m6,431-766 -839.2%  
Depreciation Rs m1,055711 148.3%   
Interest Rs m341,503 2.3%   
Profit before tax Rs m5,413-2,881 -187.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-81-6 1,419.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,20417 7,163.7%   
Profit after tax Rs m4,128-1,121 -368.2%  
Gross profit margin %20.5-14.9 -138.1%  
Effective tax rate %22.2-0.6 -3,812.4%   
Net profit margin %13.2-21.8 -60.6%  
BALANCE SHEET DATA
Current assets Rs m18,2473,810 478.9%   
Current liabilities Rs m11,2358,365 134.3%   
Net working cap to sales %22.4-88.4 -25.3%  
Current ratio x1.60.5 356.6%  
Inventory Days Days86156 55.0%  
Debtors Days Days6167 91.3%  
Net fixed assets Rs m20,03514,480 138.4%   
Share capital Rs m37761 615.0%   
"Free" reserves Rs m21,824903 2,416.6%   
Net worth Rs m22,2015,127 433.0%   
Long term debt Rs m5,0005,832 85.7%   
Total assets Rs m39,41119,433 202.8%  
Interest coverage x160.2-0.9 -17,478.9%   
Debt to equity ratio x0.21.1 19.8%  
Sales to assets ratio x0.80.3 299.6%   
Return on assets %10.62.0 537.7%  
Return on equity %18.6-21.9 -85.0%  
Return on capital %19.73.6 542.5%  
Exports to sales %46.424.5 189.3%   
Imports to sales %10.510.2 103.1%   
Exports (fob) Rs m14,5351,264 1,150.1%   
Imports (cif) Rs m3,288525 626.6%   
Fx inflow Rs m14,7221,539 956.4%   
Fx outflow Rs m7,026942 745.8%   
Net fx Rs m7,696597 1,288.6%   
CASH FLOW
From Operations Rs m3,124599 521.4%  
From Investments Rs m-8,844-438 2,019.6%  
From Financial Activity Rs m5,026-303 -1,661.0%  
Net Cashflow Rs m-693-141 490.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.6 483.3%  
FIIs % 9.1 1.3 700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.6 58.9%  
Shareholders   49,328 10,259 480.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Mar 22, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS